Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
883.2 USD -0.84% Intraday chart for Regeneron Pharmaceuticals, Inc. -1.52% +0.56%
Apr. 26 Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says MT
Apr. 26 Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 41,049 50,990 66,029 77,057 93,403 95,284 - -
Enterprise Value (EV) 1 35,291 50,098 56,196 77,057 84,542 86,606 81,922 77,197
P/E ratio 20.3 x 15.8 x 8.77 x 18.9 x 25.3 x 23.9 x 22.6 x 18.9 x
Yield - - - - - - - -
Capitalization / Revenue 5.22 x 6 x 4.11 x 6.33 x 7.12 x 6.85 x 6.41 x 5.94 x
EV / Revenue 4.49 x 5.9 x 3.5 x 6.33 x 6.45 x 6.23 x 5.51 x 4.81 x
EV / EBITDA 10.3 x 11.8 x 5.71 x 12.7 x 15.2 x 15.6 x 13.6 x 11.4 x
EV / FCF 17.6 x 25 x 8.61 x 17.4 x 21.8 x 18.2 x 17.4 x 14.4 x
FCF Yield 5.67% 4% 11.6% 5.74% 4.58% 5.49% 5.76% 6.97%
Price to Book 3.7 x 4.71 x 3.56 x 3.41 x 3.64 x 3.28 x 2.8 x 2.4 x
Nbr of stocks (in thousands) 109,323 105,544 104,556 106,802 106,347 107,886 - -
Reference price 2 375.5 483.1 631.5 721.5 878.3 883.2 883.2 883.2
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 7,863 8,497 16,072 12,173 13,117 13,907 14,861 16,038
EBITDA 1 3,420 4,244 9,835 6,060 5,547 5,538 6,033 6,754
EBIT 1 2,210 3,577 8,947 5,719 5,126 5,230 5,571 6,224
Operating Margin 28.1% 42.09% 55.67% 46.98% 39.08% 37.6% 37.49% 38.81%
Earnings before Tax (EBT) 1 2,429 3,810 9,326 4,859 4,199 4,720 4,977 5,652
Net income 1 2,116 3,513 8,075 4,338 3,954 4,320 4,531 5,371
Net margin 26.91% 41.35% 50.25% 35.64% 30.14% 31.06% 30.49% 33.49%
EPS 2 18.46 30.52 71.97 38.22 34.77 36.89 39.01 46.70
Free Cash Flow 1 2,000 2,004 6,529 4,425 3,875 4,752 4,716 5,379
FCF margin 25.44% 23.58% 40.63% 36.35% 29.54% 34.17% 31.74% 33.54%
FCF Conversion (EBITDA) 58.5% 47.2% 66.39% 73.01% 69.86% 85.8% 78.17% 79.64%
FCF Conversion (Net income) 94.55% 57.03% 80.86% 101.99% 98.02% 110% 104.1% 100.15%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 3,453 4,952 2,965 2,857 2,936 3,414 3,162 3,158 3,363 3,434 3,222 3,408 3,576 3,732 3,582
EBITDA 1 2,057 2,903 1,558 1,344 1,488 1,637 1,315 1,351 1,488 1,395 1,195 1,320 1,440 1,606 1,290
EBIT 1 1,847 2,640 1,483 1,285 1,413 1,537 1,215 1,248 1,382 1,282 1,170 1,262 1,376 1,444 1,400
Operating Margin 53.5% 53.31% 50.03% 44.99% 48.12% 45.02% 38.43% 39.51% 41.11% 37.33% 36.3% 37.04% 38.49% 38.68% 39.09%
Earnings before Tax (EBT) 1 1,817 2,503 1,061 963.2 1,510 1,325 858 1,083 1,111 1,148 1,212 1,304 1,432 1,287 -
Net income 1 1,632 2,229 973.5 852.1 1,316 1,197 817.8 968.4 1,008 1,160 888.3 1,032 1,179 1,264 1,283
Net margin 47.27% 45.01% 32.83% 29.82% 44.81% 35.06% 25.86% 30.66% 29.97% 33.77% 27.57% 30.28% 32.98% 33.87% 35.82%
EPS 2 14.33 19.69 8.610 7.470 11.66 10.50 7.170 8.500 8.890 10.19 7.910 9.194 10.01 10.21 11.49
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/4/22 5/4/22 8/3/22 11/3/22 2/3/23 5/4/23 8/3/23 11/2/23 2/2/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 5,757 891 9,833 - 8,862 8,679 13,362 18,087
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 2,000 2,004 6,529 4,425 3,875 4,752 4,716 5,379
ROE (net income / shareholders' equity) 28.5% 33.2% 54.2% 24.9% 20.7% 18.7% 17.3% 16.7%
ROA (Net income/ Total Assets) 15.9% 22% 37.9% 18.9% 16.2% 12% 11.9% 12.5%
Assets 1 13,270 15,984 21,299 22,956 24,412 35,907 38,226 42,921
Book Value Per Share 2 102.0 102.0 178.0 212.0 241.0 269.0 315.0 369.0
Cash Flow per Share 2 21.20 22.70 63.10 44.20 40.40 48.80 48.60 57.80
Capex 1 430 615 552 590 719 853 799 765
Capex / Sales 5.46% 7.23% 3.43% 4.85% 5.48% 6.13% 5.38% 4.77%
Announcement Date 2/6/20 2/5/21 2/4/22 2/3/23 2/2/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
883.2 USD
Average target price
1,038 USD
Spread / Average Target
+17.54%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.71% 8.24B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Financials Regeneron Pharmaceuticals, Inc.